A drug long prescribed for a rare lung condition has revealed an unexpected capacity to interrupt one of cancer's most lethal maneuvers — the ability to spread. Researchers at the University of São Paulo found that ambrisentan, already approved for pulmonary hypertension, significantly reduced tumor migration and extended survival across multiple cancer types in laboratory and animal studies. The discovery invites a familiar question in medicine: whether a molecule shaped for one disease might quietly hold answers for another, and whether the path from animal model to human benefit will prove
News-Medical.net
· Dec 15, 2020
· health
· 2 min de leitura
High
Apuração: Caracterizado
Pulmonary hypertension drug shows promise in blocking cancer metastasis
◉
Health & Medicine
8358 artigos relacionados
Retatrutide: Eli Lilly's Triple-Action Weight-Loss Drug Poised to Resh…
The Economic Times · 100% correspondência
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight-Loss Treatment
Interesting Engineering · 99% correspondência
Eli Lilly's Oral GLP-1 Pill Shows Promise for Diabetes and Weight Loss
TODAY · 99% correspondência
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight Loss Drug
ScienceAlert · 99% correspondência
Moderna's personalized mRNA melanoma vaccine shows promise in preventi…
CBS News · 99% correspondência
Cobertura Relacionada
The Guardian · Aug 24
UK approves daily GLP-1 pill for diabetes and weight loss amid counterfeit drug warnings
Foundayo, a new daily pill treating diabetes and aiding weight loss, launches in UK pharmacies Monday. Pharmacists welco…
Mirage News · Aug 24 Study reveals type 2 diabetes in lean Africans requires different treatment approachResearch reveals type 2 diabetes in lean Africans stems from insulin deficiency, not resistance, yet they receive the sa…
Mirage News · Aug 24 Australian researchers identify existing drugs to slow rare childhood dementiaAustralian researchers identified nine existing TGA-approved medicines that could slow brain damage in children with San…
The New Indian Express · Aug 24 Odisha leads national push to prevent metabolic liver disease affecting 1 in 3 IndiansLeading gastroenterology and hepatology experts convened in Odisha to finalize national guidelines for preventing metabo…
Viés e Enquadramento
Não há dados de análise detalhada para esta lente. Tente executar as lentes novamente no painel de administração.
Impacto Geopolítico
🌎
Medical research on cancer drug repurposing has no direct geopolitical implications; this is a scientific advancement with potential healthcare benefits across nations.
Escalation Risk
low
Confidence
HIGH
No shifts in international power, alliances, or influence. This is biomedical research with global collaborative potential (Brazil-Germany-UAE partnership demonstrates open scientific cooperation).
Lente Econômica
📈
Pulmonary hypertension drug ambrisentan shows 47% reduction in cancer metastasis in animal trials, potentially opening new oncology treatment pathway and creating pharmaceutical repurposing opportunity.
Market Signal
bullish
Confidence
MED
Pharmaceutical/Biotechnology
Healthcare/Oncology
Medical Devices and Diagnostics
Patients with advanced cancers could gain access to a new treatment option with potentially fewer side effects than traditional chemotherapy if clinical trials succeed. However, benefits remain speculative until human trials demonstrate efficacy and safety.
FDA may expedite clinical trial pathways for drug repurposing given existing safety data from pulmonary hypertension use. Patent and exclusivity considerations for off-label use could emerge. Healthcare systems may need to evaluate cost-effectiveness of combination therapies.